Skip to main content

Advertisement

Springer Nature Link
Log in

A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

The only systematic in vivo studies comparing antipsychotic (AP) effects on nucleus accumbens (NAc) shell and core dopamine (DA) transmission are voltammetric studies performed in pargyline-pretreated, halothane-anaesthetized rats. Studies in freely moving rats not pretreated with pargyline are not available. This study was intended to fill this gap by the use of in vivo microdialysis in freely moving rats.

Methods

Male Sprague-Dawley rats were implanted with microdialysis probes in the NAc shell and core and medial prefrontal cortex (PFCX). The next day, rats were administered intravenously with two or three doses of APs, and dialysate DA was monitored in 10-min samples. Some rats were pretreated with pargyline (75 mg/kg i.p.) and after 1 h were given clozapine or risperidone.

Results

Clozapine, risperidone, quetiapine, raclopride, sulpiride and amisulpride increased DA preferentially in the NAc shell. Such preferential effect on shell DA was not observed after haloperidol, chlorpromazine and olanzapine. In contrast to voltammetric studies, a preferential effect on NAc core DA was not observed after any dose of AP. Pargyline pretreatment did not reduce but actually amplified the preferential effect of clozapine and risperidone on NAc shell DA.

Conclusions

Apart from raclopride and olanzapine, the APs with lower extrapyramidal effects could be distinguished from typical APs on the basis of their ability to preferentially stimulate DA transmission in the NAc shell. There was no relationship between stimulation of PFCX DA and atypical APs profile. The differences between this study and voltammetry studies were not attributable to pargyline pretreatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  • Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatr J Assoc Eur Psychiatrists 20:15–27

    Article  Google Scholar 

  • Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci Off J Soc Neurosci 22:3708–3719

    CAS  Google Scholar 

  • Adachi YU, Aramaki Y, Satomoto M, Higuchi H, Watanabe K (2003) Halothane attenuated haloperidol and enhanced clozapine-induced dopamine release in the rat striatum. Neurochem Int 43:113–119

    Article  CAS  PubMed  Google Scholar 

  • Adachi YU, Yamada S, Satomoto M, Higuchi H, Watanabe K, Kazama T, Mimuro S, Sato S (2008) Isoflurane anesthesia inhibits clozapine- and risperidone-induced dopamine release and anesthesia-induced changes in dopamine metabolism was modified by fluoxetine in the rat striatum: an in vivo microdialysis study. Neurochem Int 52:384–391

    Article  CAS  PubMed  Google Scholar 

  • Anden NE, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346–348

    Article  CAS  PubMed  Google Scholar 

  • Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303–314

    Article  CAS  PubMed  Google Scholar 

  • Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathe JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn Schmiedeberg’s Arch Pharmacol 352:374–385

    Article  CAS  Google Scholar 

  • Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 18:63–101

    Article  CAS  Google Scholar 

  • Axelsson R, Nilsson A, Christensson E, Bjork A (1991) Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology 104:287–292

    Article  CAS  PubMed  Google Scholar 

  • Balant-Gorgia AE, Balant L (1987) Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 13:65–90

    Article  CAS  PubMed  Google Scholar 

  • Bartholini G (1976) Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol 28:429–433

    Article  CAS  PubMed  Google Scholar 

  • Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14:187–202

    Article  CAS  PubMed  Google Scholar 

  • Bunney BS (1988) Effects of acute and chronic neuroleptic treatment on the activity of midbrain dopamine neurons. Ann N Y Acad Sci 537:77–85

    Article  CAS  PubMed  Google Scholar 

  • Byerly MJ, DeVane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16:177–187

    Article  CAS  PubMed  Google Scholar 

  • Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003) Muscarinic mechanisms of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry 27:1125–1143

    Article  CAS  Google Scholar 

  • Calipari ES, Huggins KN, Mathews TA, Jones SR (2012) Conserved dorsal-ventral gradient of dopamine release and uptake rate in mice, rats and rhesus macaques. Neurochem Int 61:986–991

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Carboni E, Rolando MT, Silvagni A, Di Chiara G (2000) Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 22:140–147

    Article  CAS  Google Scholar 

  • Carlsson A (1974) Antipsychotic drugs and catecholamine synapses. J Psychiatr Res 11:57–64

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Article  CAS  Google Scholar 

  • Cassano GB, Castrogiovanni P, Conti L, Bonollo L (1975) Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. Curr Ther Res Clin Exp 17:189–201

    CAS  PubMed  Google Scholar 

  • Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 88:63–72

    Article  PubMed  Google Scholar 

  • Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci Off J Soc Neurosci 3:1607–1619

    CAS  Google Scholar 

  • Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, Pfefferbaum A, Faustman WO (1994) Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Psychopharmacology 116:291–296

    Article  CAS  PubMed  Google Scholar 

  • Deutch AY, Cameron DS (1992) Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience 46:49–56

    Article  CAS  PubMed  Google Scholar 

  • Deutch AY, Lee MC, Iadarola MJ (1992) Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332–341

    Article  CAS  PubMed  Google Scholar 

  • Di Chiara G (2002) Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 137:75–114

    Article  PubMed  Google Scholar 

  • Dilts RP Jr, Helton TE, McGinty JF (1993) Selective induction of Fos and FRA immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields. Synapse 13:251–263

    Article  CAS  PubMed  Google Scholar 

  • Dragunow M, Robertson GS, Faull RL, Robertson HA, Jansen K (1990) D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37:287–294

    Article  CAS  PubMed  Google Scholar 

  • Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, Shahid M, Wong EH, Svensson TH (2008) Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196:417–429

    Article  CAS  PubMed  Google Scholar 

  • Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686–693

    Article  PubMed  Google Scholar 

  • Ginovart N, Kapur S (2012) Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 27–52

  • Grace AA, Bunney BS, Moore H, Todd CL (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31–37

    Article  CAS  PubMed  Google Scholar 

  • Harnryd C, Bjerkenstedt L, Bjork K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA, Wik G, Aberg-Wistedt A (1984) Clinical evaluation of sulpiride in schizophrenic patients—a double-blind comparison with chlorpromazine. Acta Psychiatr Scand Suppl 311:7–30

    Article  CAS  PubMed  Google Scholar 

  • Hartter S, Huwel S, Lohmann T, Abou El Ela A, Langguth P, Hiemke C, Galla HJ (2003) How does the benzamide antipsychotic amisulpride get into the brain?—An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 28:1916–1922

    Article  Google Scholar 

  • Heimer L, Alheid GF, de Olmos JS, Groenewegen HJ, Haber SN, Harlan RE, Zahm DS (1997) The accumbens: beyond the core-shell dichotomy. J Neuropsychiatry Clin Neurosci 9:354–381

    Article  CAS  PubMed  Google Scholar 

  • Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124:74–86

    Article  CAS  PubMed  Google Scholar 

  • Ichikawa J, Meltzer HY (1992) Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 58:2285–2291

    Article  CAS  PubMed  Google Scholar 

  • Ichikawa J, Meltzer HY (2000) The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 858:252–263

    Article  CAS  PubMed  Google Scholar 

  • Ichikawa J, Kuroki T, Dai J, Meltzer HY (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 351:163–171

    Article  CAS  PubMed  Google Scholar 

  • Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521–1531

    Article  CAS  PubMed  Google Scholar 

  • Imperato A, Angelucci L (1989) The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull 25:383–389

    CAS  PubMed  Google Scholar 

  • Imperato A, Di Chiara G (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci Off J Soc Neurosci 5:297–306

    CAS  Google Scholar 

  • Jann MW, Grimsley SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161–176

    Article  CAS  PubMed  Google Scholar 

  • Javaid JI (1994) Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol 34:286–295

    Article  CAS  PubMed  Google Scholar 

  • Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH (2011) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 28:2490–2504

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Jones SR, O’Dell SJ, Marshall JF, Wightman RM (1996) Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse 23:224–231

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360–369

    Article  CAS  PubMed  Google Scholar 

  • Knable MB, Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11:123–131

    Article  CAS  PubMed  Google Scholar 

  • Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774–781

    CAS  PubMed  Google Scholar 

  • Lecca D, Cacciapaglia F, Valentini V, Gronli J, Spiga S, Di Chiara G (2006) Preferential increase of extracellular dopamine in the rat nucleus accumbens shell as compared to that in the core during acquisition and maintenance of intravenous nicotine self-administration. Psychopharmacology 184:435–446

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962

    Article  CAS  PubMed  Google Scholar 

  • Liegeois JF, Ichikawa J, Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157–165

    Article  CAS  PubMed  Google Scholar 

  • Linnet K, Ejsing TB (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 18:157–169

    Article  CAS  Google Scholar 

  • Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos Biol Fate Chem 21:1134–1141

    CAS  PubMed  Google Scholar 

  • Marcus MM, Nomikos GG, Svensson TH (1996) Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 6:29–38

    Article  CAS  Google Scholar 

  • Marcus MM, Nomikos GG, Svensson TH (2000) Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 10:245–253

    Article  CAS  Google Scholar 

  • Marcus MM, Malmerfelt A, Nyberg S, Svensson TH (2002) Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 12:379–386

    Article  CAS  Google Scholar 

  • Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G (1996) A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf Int J Med Toxicol Drug Experience 14:288–298

    Article  CAS  Google Scholar 

  • Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263–287

    Article  CAS  PubMed  Google Scholar 

  • Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755–1760

    Article  CAS  PubMed  Google Scholar 

  • Morris ED, Normandin MD, Schiffer WK (2008) Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol Imaging Biol MIB Off Publ Acad Mol Imaging 10:67–73

    Article  Google Scholar 

  • Muly EC, Votaw JR, Ritchie J, Howell LL (2012) Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 341:81–89

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Narendran R, Jedema HP, Lopresti BJ, Mason NS, Gurnsey K, Ruszkiewicz J, Chen CM, Deuitch L, Frankle WG, Bradberry CW (2014) Imaging dopamine transmission in the frontal cortex: a simultaneous microdialysis and [11C]FLB 457 PET study. Mol Psychiatry 19:302–310

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147–156

    Article  CAS  PubMed  Google Scholar 

  • Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97–103

    Article  PubMed  Google Scholar 

  • Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San Diego

    Google Scholar 

  • Robertson GS, Fibiger HC (1992) Neuroleptics increase c-Fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315–328

    Article  CAS  PubMed  Google Scholar 

  • Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058–1066

    CAS  PubMed  Google Scholar 

  • Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 17:1–13

    Article  CAS  PubMed  Google Scholar 

  • Rummel-Kluge C (2010) Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders. Evid Based Ment Health 13:106

    Article  PubMed  Google Scholar 

  • Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83–97

    CAS  PubMed  Google Scholar 

  • Shilliam CS, Dawson LA (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 30:372–380

    Article  CAS  Google Scholar 

  • Svartengren J, Simonsson P (1990) Receptor binding properties of amperozide. Pharmacol Toxicol 66(Suppl 1):8–11

    Article  CAS  PubMed  Google Scholar 

  • Tanda G, Di Chiara G (1998) A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci 10:1179–1187

    Article  CAS  PubMed  Google Scholar 

  • Verghese C, Kessel JB, Simpson GM (1991) Pharmacokinetics of neuroleptics. Psychopharmacol Bull 27:551–563

    CAS  PubMed  Google Scholar 

  • Volonte M, Monferini E, Cerutti M, Fodritto F, Borsini F (1997) BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 69:182–190

    Article  CAS  PubMed  Google Scholar 

  • White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1057

    Article  CAS  PubMed  Google Scholar 

  • Wirtshafter D, Osborn CV (2005) The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. Eur J Pharmacol 528:88–94

    Article  CAS  PubMed  Google Scholar 

  • Wu Q, Reith ME, Kuhar MJ, Carroll FI, Garris PA (2001) Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci Off J Soc Neurosci 21:6338–6347

    CAS  Google Scholar 

  • Zahm DS (2000) An integrative neuroanatomical perspective on some subcortical substrates of adaptive responding with emphasis on the nucleus accumbens. Neurosci Biobehav Rev 24:85–105

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Research Council of Italy (CNR), by the Ministero dell’Università e della Ricerca (MURST/MIUR) and by the Regione Autonoma della Sardegna (RAS).

Conflict of interest

Authors do not have any conflict of interest to declare.

Author information

Author notes

  1. Gianluigi Tanda

    Present address: Medication Development Program, National Institute on Drug Abuse/Intramural Research Program/National Institutes of Health/Department of Health and Human Services, Baltimore, MD, USA

Authors and Affiliations

  1. Department of Biomedical Sciences, Section of Neuropsychopharmacology, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy

    Gianluigi Tanda, Valentina Valentini, Maria Antonietta De Luca, Valentina Perra, Gian Pietro Serra & Gaetano Di Chiara

  2. Centre of Excellence “Neurobiology of Addiction”, University of Cagliari, Cagliari, Italy

    Valentina Valentini & Gaetano Di Chiara

  3. National Institute of Neuroscience (INN), University of Cagliari, Cagliari, Italy

    Valentina Valentini, Maria Antonietta De Luca & Gaetano Di Chiara

  4. Neuroscience Institute, Cagliari Section, National Research Council of Italy, Cagliari, Italy

    Gaetano Di Chiara

Authors
  1. Gianluigi Tanda
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Valentina Valentini
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Maria Antonietta De Luca
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Valentina Perra
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Gian Pietro Serra
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Gaetano Di Chiara
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Gaetano Di Chiara.

Additional information

Gianluigi Tanda and Valentina Valentini contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanda, G., Valentini, V., De Luca, M.A. et al. A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics. Psychopharmacology 232, 1427–1440 (2015). https://doi.org/10.1007/s00213-014-3780-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3780-2

Keywords

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy